Project Grant R01HL181065
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Texas Southwestern Medical Center $718,548 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endothelial FLI1 in ischemic heart disease. The funded research examines how Friend Leukemia Integration 1 (FLI1), a transcription factor, governs endothelial cell function and protects against myocardial damage under ischemic stress. Preliminary data using...
- The National Heart, Lung, and Blood Institute awarded the University of Texas Southwestern Medical Center $811,633 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endotrophin in heart failure with preserved ejection fraction. The recipient will conduct basic and translational research examining endotrophin (ETP), a bioactive cleavage product of collagen VI, as a molecular driver of heart failure with preserved ejection fraction...
- The National Heart, Lung, and Blood Institute awarded Texas Tech University $594,288 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate YAP/TAZ signaling pathways in vascular smooth muscle cell adhesion and migration as a preventive and therapeutic strategy for atherosclerosis. The research comprises three aims. Aim 1 will define how extracellular matrix mechanics regulate vascular smooth muscle cell mechanotransduction. Aim 2 will assess how...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Texas Southwestern Medical Center a $1.62 million Project Grant on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate circulating metabolites underlying cardiometabolic risk for cardiac dysfunction and heart failure in diverse populations. The research employs metabolomics and genomics to identify biologic pathways linking metabolic...
- The National Heart, Lung, and Blood Institute awarded The University of North Texas Health Science Center at Fort Worth $426,550 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a bioengineering modular gene delivery system for lung-targeted transgene expression. The project addresses systemic gene therapy for monogenic lung diseases including cystic fibrosis, alpha-1-antitrypsin deficiency, and pulmonary arterial hypertension. The recipient...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $111,111 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms linking endoplasmic reticulum stress, lipid accumulation, and vascular inflammation in atherosclerosis. The research defines how the NCK1 adaptor protein integrates mechanical and metabolic stress to drive endothelial dysfunction. Aim 1 investigates how NCK1...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $608,173 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the stretch-activated PIEZO1 channel in heart failure-associated atrial fibrillation. The research comprises three aims: testing the hypothesis that atrial stretch-induced PIEZO1 activation contributes to pathological atrial remodeling and atrial fibrillation predisposition...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $246,000 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-specific differences in subclinical cardiovascular disease phenotypes and their relationship to psychosocial stress. The recipient will develop expertise in subclinical atherosclerosis measures and cardiovascular imaging phenotypes while examining whether chronic psychosocial...
- The National Heart, Lung, and Blood Institute awarded The Research Foundation For The State University Of New York (doing business as SUNY Downstate Health Sciences University) $799,659 on August 1, 2026, as a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will conduct research on the effect of SPTLC3 (serine palmitoyltransferase long-chain base subunit 3) on aging- and diet-induced insulin resistance and atherosclerosis. The work examines the...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $234,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025 through July 31, 2027. The research will investigate the force transduction mechanisms of leukocyte function-associated antigen-1 (LFA-1), a critical CD18 integrin that mediates immune cell adhesion, migration, and...
The National Heart Lung and Blood Institute awarded The University of Texas Southwestern Medical Center $662,275 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate ether lipid salvage mechanisms through the ACAD10 enzyme. The research examines how mammalian ACAD10 and its paralog ACAD11 regulate the salvage of dietary ether lipids—specialized membrane lipids that constitute up to 20 percent of the phospholipid pool in eukaryotic cells and play roles in inflammatory signaling, blood clot regulation, and oxidative stress response. Prior work in C. elegans and mice demonstrated that ACAD10 loss results in decreased basal ether lipid levels and complete loss of dietary ether lipid salvage capacity. The project will extend these findings to mammals by investigating the phosphorylation of 1-O-alkylglycerol and dephosphorylation of 1-O-alkyl-2-acetyl-3-phosphate, enzymatic steps previously uncharacterized in mammals. Work is performed in Dallas, Texas at UT Southwestern's campus. The period of performance runs from August 17, 2026, through April 30, 2030. UT Southwestern operates as a state-controlled nonprofit academic medical center and holds no SBA designations. The institution maintains a substantial research portfolio anchored by NIH funding, with the National Heart Lung and Blood Institute funding 223 awards across the center.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $662.3k | 8/19/26 |